Glancy Binkow & Goldberg LLP Reminds Investors of the Lead Plaintiff Deadline in the Class Action Lawsuit Against Omnicell, I...
April 21 2015 - 10:30AM
Business Wire
Glancy Binkow & Goldberg LLP reminds investors in Omnicell,
Inc. (“Omnicell” or the “Company”) (NASDAQ: OMCL) who purchased the
Company’s between May 2, 2014 and March 2, 2015, inclusive (the
“Class Period”) of the May 18, 2015 deadline, to file a motion to
be appointed as lead plaintiff in the shareholder lawsuit.
Investors who purchased Omnicell shares during the Class Period
are encouraged to contact Casey Sadler of Glancy Binkow &
Goldberg LLP, 1925 Century Park East, Suite 2100, Los Angeles,
California 90067, at (310) 201-9150, by e-mail to
shareholders@glancylaw.com, or visit our website
at http://www.glancylaw.com. If you inquire by email, please
include your mailing address, telephone number and number of shares
purchased. If you are a member of the Class described above, you
may move the Court no later than May 18, 2015 to serve as lead
plaintiff, if you meet certain legal requirements. To be a member
of the Class, you need not take any action at this time; you may
retain counsel of your choice or take no action and remain an
absent member of the Class.
Omnicell provides automation and business information solutions
designed to enable hospitals and long-term healthcare facilities to
acquire, manage, dispense and administer medications and
medical-surgical supplies. The Complaint alleges that defendants
made false and misleading statements or failed to disclose material
adverse facts, including the existence of a “side letter”
arrangement with a Company customer for certain discounts and
Company products that were to be provided at no cost, but which
were not reflected in the final invoices paid by the customer; and,
that the Company lacked adequate internal controls over financial
reporting. On March 2, 2015, the Company announced the need to
delay the filing of its annual report, because of the alleged “side
letter” arrangement described above. Following disclosure of the
above news, Omnicell shares fell $2.14 per share, or more than 6%,
on March 3, 2015.
This press release may be considered Attorney Advertising in
some jurisdictions under the applicable law and ethical rules.
Glancy Binkow & Goldberg LLP, Los AngelesCasey Sadler,
310-201-9150 or
888-773-9224shareholders@glancylaw.comwww.glancylaw.com
Omnicell (NASDAQ:OMCL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Omnicell (NASDAQ:OMCL)
Historical Stock Chart
From Apr 2023 to Apr 2024